EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure

Ekaterina Koksharova, Roman Drai, Sergei Noskov, Artem Dorotenko, Ekaterina Protsenko, Kseniia Radaeva, Anna Arefeva, Maria Gefen, Gagik Galstyan, Igor Makarenko

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1401 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Ekaterina Koksharova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Research Center, Moscow, Russia. Hauptthemen laut MEDLINE: Glucose Clamp Technique, Cross-Over Studies, Blood Glucose, Insulin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of the study was to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of T‐glu (GP40321, test drug), and reference insulin glulisine in a hyperinsulinemic‐euglycemic clamp procedure. During this study, 34 healthy male volunteers underwent the hyperinsulinemic‐euglycemic clamp procedure following subcutaneous 0.3 U/kg injection of T‐glu or reference insulin glulisine in a randomized, double‐blind, crossover study. Plasma glucose levels were monitored every 5 minutes for 8 hours. Glucose infusion rate adjustment was based on the blood glucose measurements. Evaluation of PD was performed using the glucose infusion rate values, while PK was calculated using insulin concentrations measured via enzyme‐linked immunosorbent assay. The study results showed that the 90% CI for the geometric mean ratios of primary PK and PD of T‐glu and reference insulin glulisine were within 80%‐125% comparability limits, and that the safety profiles were comparable. PK, PD, and safety similarity of T‐glu and reference insulin glulisine was demonstrated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucose Clamp TechniqueCross-Over StudiesBlood GlucoseInsulinHumansMaleDouble-Blind MethodAdultYoung AdultBiosimilar PharmaceuticalsHypoglycemic AgentsHealthy Volunteers

Stichwörter der Autor:innen

bioequivalencebiosimilareuglycemic clampglucodynamicsinsulin glulisinepharmacodynamicspharmacokinetics

Substanzen

insulin glulisineBlood GlucoseInsulinBiosimilar PharmaceuticalsHypoglycemic Agents

Autor:innen und Institutionen

  • Endocrinology Research Center, Moscow, Russia.
  • R&D Center, GEROPHARM, Saint-Petersburg, Russia.
  • City Hospital No. 3, Yaroslavl, Russia.

Zitieren

APA

Koksharova, E., Drai, R., Noskov, S., Dorotenko, A., Protsenko, E., Radaeva, K., Arefeva, A., Gefen, M., Galstyan, G., & Makarenko, I. (2024). Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1401

Vancouver

Koksharova E, Drai R, Noskov S, Dorotenko A, Protsenko E, Radaeva K, et al. Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1401

BibTeX
@article{Koksharova2024,
  author = {Koksharova, Ekaterina and Drai, Roman and Noskov, Sergei and Dorotenko, Artem and Protsenko, Ekaterina and Radaeva, Kseniia and Arefeva, Anna and Gefen, Maria and Galstyan, Gagik and Makarenko, Igor},
  title = {Clinical Pharmacology of GP40321 (Insulin Glulisine Biosimilar): Pharmacokinetic and Pharmacodynamic Comparability in a Hyperinsulinemic‐Euglycemic Clamp Procedure},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1401}
}
Kostenlos starten →